Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.

Teresa Magnes; Thomas Melchardt; Clemens Hufnagl; Lukas Weiss; C Mittermair; Daniel Neureiter; Eckhard Klieser; Gabriel Rinnerthaler; S Roesch; Alexander Gaggl; Richard Greil; Alexander Egle

doi:10.1038/s41397-019-0073-5

Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.

Teresa Magnes (Erstautor/-in), Thomas Melchardt (Erstautor/-in), Clemens Hufnagl (Co-Autor/-in), Lukas Weiss (Co-Autor/-in), C Mittermair, Daniel Neureiter (Co-Autor/-in), Eckhard Klieser (Co-Autor/-in), Gabriel Rinnerthaler (Co-Autor/-in), S Roesch (Co-Autor/-in), Alexander Gaggl (Co-Autor/-in), Richard Greil (Co-Autor/-in), Alexander Egle^* (Letztautor/-in)

^*Korrespondierende/r Autor/-in für diese Arbeit

Publikation: Beitrag in Fachzeitschrift › Korrektur › Begutachtung

Originalsprache	Englisch
Seiten (von - bis)	350
Fachzeitschrift	PHARMACOGENOMICS J
Jahrgang	20
Ausgabenummer	2
DOIs	https://doi.org/10.1038/s41397-019-0073-5
Publikationsstatus	Veröffentlicht - 2020

Zugriff auf Dokument

10.1038/s41397-019-0073-5

Dieses zitieren

Magnes, T., Melchardt, T., Hufnagl, C., Weiss, L., Mittermair, C., Neureiter, D., Klieser, E., Rinnerthaler, G., Roesch, S., Gaggl, A., Greil, R., & Egle, A. (2020). Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab. PHARMACOGENOMICS J, 20(2), 350. https://doi.org/10.1038/s41397-019-0073-5

@article{6e6fc6e89adc4a45b48fc2543309059d,

title = "Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.",

author = "Teresa Magnes and Thomas Melchardt and Clemens Hufnagl and Lukas Weiss and C Mittermair and Daniel Neureiter and Eckhard Klieser and Gabriel Rinnerthaler and S Roesch and Alexander Gaggl and Richard Greil and Alexander Egle",

note = "Magnes; Melchardt; Hufnagl; Weiss; Mittermair; Rinnerthaler; Greil, Egle: Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University, Salzburg, Austria; Neureiter: Institute of Pathology, Paracelsus Medical University, Salzburg, Austria; Riesch: Department of Otorhinolaryngology, Head and Neck Surgery, Paracelsus Medical University Salzburg, Salzburg, Austria; Gaggl: Department of Oral and Maxillofacial Surgery, Paracelsus Medical University Salzburg, Salzburg, Austria",

year = "2020",

doi = "10.1038/s41397-019-0073-5",

language = "English",

volume = "20",

pages = "350",

journal = "PHARMACOGENOMICS J",

issn = "1470-269X",

number = "2",

}

Magnes, T , Melchardt, T , Hufnagl, C , Weiss, L, Mittermair, C, Neureiter, D , Klieser, E , Rinnerthaler, G , Roesch, S , Gaggl, A , Greil, R & Egle, A 2020, 'Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.', PHARMACOGENOMICS J, Jg. 20, Nr. 2, S. 350. https://doi.org/10.1038/s41397-019-0073-5

Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab. / Magnes, Teresa (Erstautor/-in); Melchardt, Thomas (Erstautor/-in); Hufnagl, Clemens (Co-Autor/-in) et al.
in: PHARMACOGENOMICS J, Jahrgang 20, Nr. 2, 2020, S. 350.

Publikation: Beitrag in Fachzeitschrift › Korrektur › Begutachtung

TY - JOUR

T1 - Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.

AU - Magnes, Teresa

AU - Melchardt, Thomas

AU - Hufnagl, Clemens

AU - Weiss, Lukas

AU - Mittermair, C

AU - Neureiter, Daniel

AU - Klieser, Eckhard

AU - Rinnerthaler, Gabriel

AU - Roesch, S

AU - Gaggl, Alexander

AU - Greil, Richard

AU - Egle, Alexander

N1 - Magnes; Melchardt; Hufnagl; Weiss; Mittermair; Rinnerthaler; Greil, Egle: Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University, Salzburg, Austria; Neureiter: Institute of Pathology, Paracelsus Medical University, Salzburg, Austria; Riesch: Department of Otorhinolaryngology, Head and Neck Surgery, Paracelsus Medical University Salzburg, Salzburg, Austria; Gaggl: Department of Oral and Maxillofacial Surgery, Paracelsus Medical University Salzburg, Salzburg, Austria

PY - 2020

Y1 - 2020

U2 - 10.1038/s41397-019-0073-5

DO - 10.1038/s41397-019-0073-5

M3 - Correction

C2 - 30659276

SN - 1470-269X

VL - 20

SP - 350

JO - PHARMACOGENOMICS J

JF - PHARMACOGENOMICS J

IS - 2

ER -